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Abstract
Objective: We explore the role of DNA methylation in Alzheimer’s disease
(AD). To elucidate where DNA methylation falls along the causal pathway link-
ing risk factors to disease, we examine causal models to assess its role in the
pathology of AD. Methods: DNA methylation profiles were generated in 740
brain samples using the Illumina HumanMet450K beadset. We focused our
analysis on CpG sites from 11 AD susceptibility gene regions. The primary out-
come was a quantitative measure of neuritic amyloid plaque (NP), a key early
element of AD pathology. We tested four causal models: (1) independent asso-
ciations, (2) CpG mediating the association of a variant, (3) reverse causality,
and (4) genetic variant by CpG interaction. Results: Six genes regions (17
CpGs) showed evidence of CpG associations with NP, independent of genetic
variation – BIN1 (5), CLU (5), MS4A6A (3), ABCA7 (2), CD2AP (1), and
APOE (1). Together they explained 16.8% of the variability in NP. An interac-
tion effect was seen in the CR1 region for two CpGs, cg10021878 (P = 0.01)
and cg05922028 (P = 0.001), in relation to NP. In both cases, subjects with the
risk allele rs6656401AT/AA display more methylation being associated with more
NP burden, whereas subjects with the rs6656401TT protective genotype have an
inverse association with more methylation being associated with less NP.
Interpretation: These observations suggest that, within known AD susceptibility
loci, methylation is related to pathologic processes of AD and may play a lar-
gely independent role by influencing gene expression in AD susceptibility loci.
Introduction
Genome-wide association studies have recently identified
nineteen genes in which genetic variation influence sus-
ceptibility to Alzheimer’s disease (AD [MIM104300]).1–8
The functional consequences of some of the genomic
variants is being elaborated, such as the role of APOE
(MIM 107741), ABCA7 (MIM 605414), CD2AP (MIM
604241), CR1 (MIM 120620), CD33 (MIM 159590), and
PICALM (MIM 603025) in neuritic plaque (NP) pathol-
ogy,9–11 a key early feature in the neuropathological cas-
cade leading to AD. In addition, studies examining tissue
from the cortex of AD and healthy aging brains have
shown that some of the risk alleles are associated with the
level of RNA expression of nearby genes, such as in the
ABCA7, BIN1 (MIM 601248), CLU (MIM 185430), and
MS4A2 (MIM 147138) loci,12–15 However, other genomic
features that influence gene expression in these loci have
not been characterized in detail for a possible role in AD
susceptibility.
In previous literature we explored the relationship
between DNA methylation and AD traits on a genome-
wide level16 and found CpGs in two known AD loci,
ABCA7 and BIN1, to be significantly associated with AD
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and NP burden on a methylome-wide level, nonetheless
on that scale we were limited by the appropriate but strin-
gent criteria of controlling for hundreds of thousands of
comparisons. Here, by limiting our analyses to known AD
loci we have the power to assess more complex models of
association. Specifically, we examine the level of methyla-
tion in known AD susceptibility loci using a large cohort
of prospectively collected, frozen brains from two cohort
studies of aging: the Rush Memory and Aging Project
(MAP) and the Religious Order Study (ROS). A sample of
the dorsolateral prefrontal cortex (DLPFC), a hub in cog-
nitive and mood circuits, was extracted from each subject,
and we show that several of the loci implicated in AD sus-
ceptibility from studies of genetic variation contain CpGs
whose level of methylation is associated with the deposi-
tion of NPs, a defining neuropathologic feature of AD.
Then, we evaluated the role genetic variation on DNA
methylation within these loci: we focused on the single-
nucleotide polymorphism (SNP) in each locus that has
previously been reported to best capture the association
with AD susceptibility (index SNPs). In several loci, such
index SNPs also influence methylation levels of nearby
CpGs. Finally, we were able to test the hypothesis that
DNA methylation levels mediate the effect of a genetic
variant in two loci: APOE and CR1. Overall, we find that
genetic variation and methylation levels have largely inde-
pendent effects on AD pathology and susceptibility, with
evidence for a haplotype-specific effect of DNA methyla-
tion in the CR1 gene region.
Materials and Methods
Subjects and materials
Subjects
Samples are from participants in two ongoing longitudinal
studies of cognition, the ROS and the Rush MAP. The
ROS, started in 1994, enrolls Catholic priests, nuns and
brothers from more than 40 groups in 12 states. On
enrollment, participants were older and free of dementia.
The MAP, started in 1997, enrolls participants from retire-
ment living communities, subsidized housing, church
groups and social service agencies throughout the Chica-
goland area. The studies have a large common core of data
designed to facilitate combination of data, and are main-
tained by a single investigative team at the Rush Alzhei-
mer’s Disease Center at Rush University Medical Center in
Chicago, IL. At the time of generation of the DNA methyl-
ation data, 1 January 2010, 2475 participants completed
baseline evaluations and 806 participants died and under-
went autopsies. Participants in each study are followed
annually with detailed clinical evaluations and have signed
both an informed consent and an Anatomical Gift Act for
donating their brains at time of death. More detailed
descriptions of each study have been published previ-
ously.17,18 Both ROS and MAP were approved by the Rush
University Medical Center institutional review board.
Genotyping
DNA was extracted from whole blood, lymphocytes, or
frozen postmortem brain tissue. Genotyping was done in
three subsets. The data for the first two subsets were gen-
erated in 2009 on the Affymetrix Genechip 6.0 platform
(Affymetrix, Inc, Santa Clara, CA, USA) at the Broad
Institute’s Center for Genotyping or the Translational Ge-
nomics Research Institute. The third subset was geno-
typed in 2012 on the Illumina HumanOmniExpress
(Illumina, Inc, San Diego, CA, USA) at the Children’s
Hospital of Philadelphia. All three data sets underwent
the same quality control (QC) analysis, described in detail
elsewhere19 and QCed genotypes were pooled.
In addition to the APOE e4 haplotype (MIM 107741),
we limited out analyses to the list of SNPs that showed a
genome-wide association with AD in previous literature
and were replicated in additional publications. These
included index SNPs from CR1 (MIM 120620;
rs6656401), PICALM (MIM 603025; rs7110631), CLU
(MIM 185430; rs11136000), ABCA7 (MIM 605414;
rs3752246), BIN1 (MIM 601248; rs744373), CD2AP
(MIM 604241; rs9349407), CD33 (MIM 159590;
rs3865444), EPHA1 (MIM 179610; rs11767557), MS4A4A
(MIM 606547; rs4938933) and MS4A6A (MIM 606548;
rs610932).1,2,4,5,7–9,20 Data on APOE were generated by
directly genotyping the two SNPs that comprise the APOE
functional haplotype.
DNA methylation
DNA methylation profiles were created from samples of
brain tissues from the DLPFC collected from 761
deceased ROS and MAP participants. Information on
experimental and QC procedures and mapping of chro-
matin state is provided in detail in previous literature.16
In brief, frozen 100 mg sections of the DLPFC sent from
the Rush Alzheimer’s Disease Center were processed at
the Broad Institute in Cambridge, MA. White matter was
carefully dissected from gray matter on the thawed sec-
tions and DNA extraction was performed using the Qia-
gen (cat: 51306, Qiagen, Inc, Valencia, CA, USA) QIAmp
DNA mini-protocol. The DNA methylation data were
generated by the Broad Institute’s Genomics Platform
using the Illumina InfiniumHumanMethylation450 bead
chip assay. The Illumina platform consists of 485,513
probes covering a total of 21,231 genes, with an average
of 17.2 probes per gene region. Data generated from the
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Illumina 450K platform were processed using the Genom-
eStudio software Methylation Module v1.8 to produce
beta-values and detection P-values for each CpG site.
Probes were discarded based on the following criteria: (1)
14,664 probes with detection P-values >0.01 indicating
poor quality, (2) 10,868 probes found on the sex chromo-
somes, (3) 29,233 probes that are predicted to cross-
hybridize with sex chromosomes based on alignment,21
and (4) 14,964 probes that overlap with known SNP sites,
limiting them to those with minor allele frequencies >1%
in a European population based on 1000 Genomes data-
base, leaving us with a total of 415,848 autosomal CpGs
for analyses. Subjects were removed from analyses if they
were deemed poor quality defined in two ways. First, we
performed a principle component analysis (PCA) on a
random selection of 50,000 probes and any subject not
within 3 SD of the mean of PC1, PC2, or PC3 was dis-
carded (n = 13 subjects). Second, subjects were excluded
based on poor bisulfite conversion (BC) efficiency,
defined as having at least two of the 10 BC control probes
fail to reach a value of 0.8 (n = 8) leaving us with 740
samples for analysis. A more detailed description of pro-
cessing the DNA methylation data is described else-
where.16
The map for the state of the chromatin was generated
in collaboration with the Epigenomics Roadmap team
(http://www.roadmapepigenomics.org/). It was derived
from samples from the DLPFC of two individuals from
the MAP study who were cognitively nonimpaired, with
minimal AD-associated pathology at time of death. Using
established methods22 the map is based on the derivation
of chromatin state in 200 bp segments using data gener-
ated from the immunoprecipitation of chromatin marks.
Pathological outcomes
The autopsy rate in ROS and MAP is over 85% and the
procedures are described in detail in previous manu-
scripts.17,18 Two pathological outcomes were used in these
analyses: (1) a quantitative measure of AD pathology based
on standardized counts of NPs, and (2) a pathological
diagnosis of AD based on intermediate or high likelihood
of AD by National Institute on Aging-Reagan criteria
using Consortium to Establish a Registry for Alzheimer’s
Disease estimates of NP density and Braak staging of neu-
rofibrillary pathology, as previously described.23,24
Models
All analyses are focused on regions around known AD
risk loci. Our primary outcome of interest is neuritic
amyloid plaque (AD pathology), with secondary analyses
on pathological diagnosis of AD.
First, we examine each side of the causal pathway, the
CpGs association with outcomes, the index SNPs associa-
tion with the outcomes and the CpGs association with
the index SNP in each gene region. Second, we explore
the four possible models of association: (1) Independent
Associations, (2) CpG-mediated effect, (3) Reverse Cau-
sality, and (4) an interaction model. The steps for each
model are described in Figure 1. With our cross-sectional
data, we are unable to distinguish between models (2)
and (3) computationally, however, we will explore each
hypothesized model individually, but limit our interpreta-
tion of (2) and (3) to the possibility of it being either
CpG-mediated effect or reverse causality. The first three
models require a significant association between the SNP
of interest and the outcome, whereas (4) the interaction
model does not; in fact, if a strong interaction effect is
present it will suppress any association between SNP and
outcome.
Statistical analysis
Patient characteristics are summarized using means and
standard deviations for continuous measures and frequen-
cies for discrete variables. A linear regression model is
used for the quantitative measure of NPs and a logistic
regression model is used for the AD pathological diagno-
sis outcome. All models are adjusted for age at death, sex,
batch, and a measure of technical variation, namely, BC
ratio. Since the NP was skewed, the measure was trans-
formed by taking the square root. Multiple comparisons
are taken into account on a gene level, using the Benja-
mini-Hochberg procedure.25 All statistical analyses were
performed using SAS version 9.3 (SAS Institute, Cary,
NC).
Results
A total of 740 subjects passed QC and were included in
the analyses. Of these, 399 (54%) were from the ROS and
341 (46%) from the MAP. The mean (SD) age at death
was 88.0 (6.7) years, 270 (36%) were male, and 447
(61%) had a pathological diagnosis of AD. We focus our
study on the index SNPs that have been reported to best
capture the association of a given locus with AD suscepti-
bility. Associations of these index SNPs to our primary
outcome, the burden of NP pathology and pathological
diagnosis of AD (AD) in our data set are presented in
Table 1.
Figure 1 outlines the four different models that we con-
sidered in our analyses. For all 11 AD susceptibility loci,
we explored whether DNA methylation is influenced by
the index SNP and also whether DNA methylation is asso-
ciated with our outcome measures, independent of genetic
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variation. Since, in our data, only the APOE and CR1 loci
demonstrate a genetic association with the outcome
measures – which is a prerequisite for testing mediation
and reverse causality – all analyses testing for evidence of
CpG-mediated effect of SNPs and reverse causality (Fig. 1,
models 2 and 3) were limited to these two loci. Finally,
for all loci, we also tested for evidence of interaction
between the index SNPs and methylation levels of the
interrogated CpGs (Fig. 1, model 4).
Assessing the relation of DNA methylation
in AD loci to AD pathology (CpG ? Y)
We first assessed whether methylation levels of CpGs
found in AD susceptibility loci are associated with our
primary outcome measure, an individual’s burden of NP
pathology (Table 1). The gene with one of the most CpGs
associated with NP burden is BIN1 with five CpGs out of
53 tested meeting the Benjamini-Hochberg corrected
threshold of significance, and four of the five showing a
positive direction, indicating more methylation is associ-
ated with higher burden of NP pathology and increased
odds of AD (Table 1 and Fig. 2). When accounting for
the CpG with the strongest association (cg22883290,
P = 3.7 9 108) two CpGs remain significant
(cg04019522, P = 0.001 and cg18981277, P = 0.002), and
when accounting for the effect of the top two,
cg22883290 and cg04019522, cg18981277, is still signifi-
cant (P = 0.003) suggesting that there are independent
effects of CpGs within this locus (Table S1 and Fig. 2). A
(1) Independent AssociaƟons
 M is associated with G
 M is associated with Y
 G and Y are not associated
 Y is associated with G
 Y is associated with M
 G and M are not associated
 G is associated with Y
 G is associated with M
 Y and M are not associated
(2) CpG mediated eﬀect
G is associated with Y & M
M is associated with Y
G is no longer associated with Y
when controlling for M
(3) Reverse Causality
 G is associated with Y & M
 Y is associated with M
 G is no longer associated with
M when controlling for Y
(4) InteracƟon Model
 G*M term is significantly
associated with Y
 M is significantly associated
with Y straƟfying by G
CpG
SNP
NeuriƟc plaque burden
or diagnosis of AD
M
(AA)
Y
M
(Aa)
M
(aa)G Y
M
G Y
M
G Y
M
G Y
M
G Y
M
M
G
Y
Figure 1. Proposed models incorporating the role of DNA methylation in Alzheimer’s disease (AD) susceptibility. Four possible models are tested:
(1) Independent associations of CpG and genetic variants with the outcome measure, (2) CpG-mediated effect in which DNA methylation
mediates the effect of a genetic variant, (3) Reverse causality in which the outcome measure (such as AD) leads to DNA methylation changes, and
(4) interaction model in which the association of a CpG varies based on a genetic variant. Note that models (2) and (3) can only be tested when
all three components of the models are associated with one another: in our data, only the CR1 and APOE loci are tested. Dashed lines represent
hypothesized associations tested in each model and solid lines are significant associations required to test the model.
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similar relationship is seen in MS4A6A, where three CpGs
out of 12 CpGs tested, are independently associated with
pathology burden and all three CpGs remain significant
when controlling for the other two, (cg03055440,
P = 0.02, cg07170641, P = 0.04, and cg18159934,
P = 0.004) (Table S1 and Fig. 3). Another locus, CLU
had five CpGs (out of 40 tested) significantly associated
with NP pathology. In this case four out of the five CpGs
showing a negative direction indicating that more methyl-
ation is associated with lower burden of NP pathology
and lower odds of AD. When accounting for the top
CpG (cg16292768, P = 3.7 9 105) one CpG remains sig-
nificant (cg20918219, P = 0.0004) suggesting that this
CpG appears to have an effect independent of the top
CpG cg16292768 (Table S1 and Fig. 4). The ABCA7,
APOE, and CD2AP loci harbor only single CpGs with a
Table 1. Associations between CpGs or index SNPs and NP burden and AD diagnosis.
SNP Position Gene
SNP to NP association SNP to AD association
P-value P-value
rs6656401 1:207692049 CR1 0.0169 1.1E-04
rs744373 2:127894615 BIN1 0.1790 0.2243
rs9349407 6:47453378 CD2AP 0.4393 0.6703
rs11767557 7:143109139 EPHA1 0.4565 0.6931
rs11136000 8:27464519 CLU 0.4878 0.4364
rs610932 11:59939307 MS4A6A 0.7040 0.8746
rs4938933 11:60034429 MS4A4A 0.9301 0.9305
rs7110631 11:85856187 PICALM 0.3863 0.5214
rs3752246 19:1056492 ABCA7 0.2102 0.6958
anye4 APOE 3.8E-23 1.6E-13
rs3865444 19:51727962 CD33 0.1233 0.0951
BIN1 (53 tested) Position Chromatin state
CpG to NP association CpG to AD association
P-value Direction* P-value Direction*
cg22883290 127800646 Weak transcribed/low signal proximal to active regions 3.7E-08 + 1.5E-05 +
cg19153828 127782651 Strong promoter 0.0002 + 0.0012 +
cg04019522 127852450 Active enhancer 0.0002 + 1.1E-04 +
cg09006514 127800616 Weak transcribed/low signal proximal to active regions 0.0013 + 0.0060 +
cg18981277 127805910 Strong transcription 0.0022  0.0232 
Position Chromatin state CpG to NP CpG to AD
CD2AP (20 tested)
cg20172563 47487173 Low signal 7.5E-06 + 0.0043 +
CLU (40 tested)
cg16292768 27467783 Active TSS flanking 3.7E-05  0.0003 
cg08594681 27468684 Active TSS flanking 8.4E-04  0.0847 
cg11783834 27469331 Active TSS flanking 0.0029  0.0976 
cg13488078 27469338 Active TSS flanking 0.0029  0.0034 
cg20918219 27493854 Weak enhancer 0.0035 + 0.0025 +
MS4A6A (12 tested)
cg03055440 59950405 Low signal 0.0015  0.0012 
cg07170641 59950068 Low signal 0.0016  0.0161 
cg18159934 59942032 Low signal 0.0030 + 0.0583 +
ABCA7 (91 tested)
cg02308560 1071176 PC repressed 3.1E-08 + 5.0E-06 +
cg04587220 1071208 PC repressed 5.0E-06 + 2.3E-04 +
APOE (41 tested)
cg18799241 45412599 Weak transcribed/low signal proximal to active regions 6.2E-04 + 0.0241 +
Only those features meeting a Benjamini-Hochberg threshold of significance are presented. All models are adjusted for age at death, sex, study,
batch effect, and bisulfide conversion QC probes. CR1 (31 CpGs), EPHA1 (60 CpGs), MS4A4A (11 CpGs), PICALM (25 CpGs) and CD33 (12 CpGs)
showed no CpGs that met multiple comparisons cutoff.
*“+” means more methylation is associated with more pathology or increased odds of AD, “” means more methylation is assoicated with less
pathology or decreased odds of AD.
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significant association, and the remaining loci had no
CpGs meeting the threshold of significance (Figs. S1–S3).
Altogether, the 17 CpGs across the six gene regions that
meet the threshold of significance explain 16.8% of the
variability in NP. By reducing the analysis to the subset
of subjects who were cognitively nonimpaired at the time
of death, we see that the effect size of many of the associ-
ated CpGs is not altered (Table S2), indicating that the
association of DNA methylation at certain sites with AD
pathology is not a feature only of the demented state.
These alterations in DNA methylation within known AD
susceptibility loci therefore occur early in the pathologic
process with BIN1, CD2AP, ABCA7, and APOE primarily
in the positive direction and CLU and MS4A6A in the
negative direction, but we cannot, at this time, distinguish
whether they are a cause or an effect of NP pathology.
AD susceptibility alleles influence DNA
methylation in the aging brain (SNP ? CpG)
Given that the selected loci all harbor genetic variation
associated with AD susceptibility in published literature,
we next assessed whether the index SNPs that have been
identified and validated in the large genome-wide associa-
tion studies influence the level of DNA methylation at the
associated CpG (Table S3). With the exception of
PICALM, all genes showed at least one CpG with an asso-
ciation to the index SNP meeting Benjamini-Hochberg
correction (Table S3). For example, in the BIN1 locus,
the index SNP (rs744373) influences the level of DNA
methylation at 13 CpGs, 25% of the probes in the BIN1
region, suggesting that the SNP has a large effect on the
methylation status of the region. However, the level of
methylation of the affected CpGs is not strongly corre-
lated with the level of NP pathology or AD susceptibility.
To explore this question more explicitly, we investigated
the possibility that the effects of SNPs and CpGs on
pathology may be largely independent of one another.
Assessing the independent association
model (1)
The first type of independent association model that
we assess is one in which the level of CpG methylation is
Figure 2. AD susceptibility loci BIN1 displays multiple, independent
associations of CpG methylation with neuritic plaque (NP) burden.
The figure represents the results of analyses for the BIN1 region, with
the physical position presented on the x axis and log10 P-values
presented in the y axis. Diamonds represent the individual CpGs
across the gene region that were tested in the analysis. The state of
the chromatin in the dorsolateral prefrontal cortex of a cognitively
nonimpaired individual is presented below the x axis; this map is
based on the derivation of chromatin state in 200 bp segments using
data generated from the immunoprecipitation of chromatin marks.
The chromatin states are defined in a box at the top right of the
figure.16 The red diamonds report the results of the primary model
relating CpG methylation and NP burden using a model adjusted for
age at death, sex, batch, study, and bisulfite conversion fraction. The
black diamonds report the results of the primary model with the
additional adjustment for the top CpG, cg22883280, to identify
secondary, independent associations such as cg04019522. The blue
diamonds report the primary model adjusted for both cg22883290
and cg04019522 showing a third independently associated CpG,
cg08663425. All P-values are reported in Table S1.
Figure 3. AD susceptibility loci MS4A6A displays multiple,
independent associations of CpG methylation with neuritic plaque
(NP) burden. The figure represents the results of analyses for the
MS4A6A region, with the physical position presented on the x axis
and log10 P-values presented in the y axis. Diamonds represent the
individual CpGs across the gene region that were tested in the
analysis. The state of the chromatin in the dorsolateral prefrontal
cortex of a cognitively nonimpaired individual is presented below the
x axis; this map is based on the derivation of chromatin state in
200 bp segments using data generated from the immunoprecipitation
of chromatin marks. The chromatin states are defined in a box at the
top right of the figure.16 The red diamonds are from the primary
model testing for NP association using a model adjusted for age at
death, sex, batch, study, and bisulfite conversion fraction. The black
diamonds report the results of the primary model with the additional
adjustment for the top CpG, cg03055440 and the blue diamonds
show the results from the primary model adjusted for the top two
independent CpGs, cg03055440 and cg1815993, showing a third
independently associated CpG, cg07170641. All P-values are reported
in Table S1.
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associated with both the index SNP and NP burden, but the
SNP and NP burden are not associated (Fig. 1, model 1).
We see multiple examples of this in three genes. For exam-
ple, in the BIN1 region, the level of methylation of one CpG
(cg22883290) is associated with the index SNP, rs744373
(P = 1.2 9 104), and the NP trait (P = 3.7 9 108)
(Table 2). While we appreciate the fact that the lack of asso-
ciation between the BIN1 SNP and NP could be due to lack
of power (pNP = 0.18, pAD = 0.22), the beta estimate for the
association between the BIN1 index SNP rs744373 and NP is
close to zero (b = 0.04) suggesting little to no association.
Nevertheless, we tested whether controlling for the SNP
modifies the association between the CpG and NP and
found that the cg22883290 association with NP remains after
adjusting for the index SNP, rs744373, (P = 5.4 9 107).
This suggests that the association between cg22883290 and
NP is independent of the BIN1 susceptibility SNP. This is a
case where the index SNP does not appear to influence the
associations between the CpG and NP.
Similarly, in the CLU region, there are three CpGs associ-
ated with both the index SNP, rs11136000, (cg16292768,
P = 1.2 9 109; cg08594681, P = 1.1 9 105; and
cg13488078, P = 0.002) and NP (P = 3.7 9 105,
8.4 9 104, and 0.003, respectively) (Table 2). Including
the CLU SNP in the model does not significantly alter the
relation of CpG and NP. As with BIN1, the index CLU SNP
is not significantly associated with NP (b = 0.02,
P = 0.48), again suggesting that the effects of CpG methyla-
tion on NP appear to be independent of AD susceptibility
alleles. The same is true in two other AD loci, CD2AP and
MS4A6A in which index SNPs influence methylation levels
(Table 2). Thus, in these AD loci, the role of susceptibility
alleles and DNA methylation appear to be largely indepen-
dent in the CpGs sampled by the array. Similar results are
found in CLU, BIN1, and MS4A6A when we consider an
AD diagnosis as the outcome measure (Table S4).
A second type of independent association occurs when
the SNP is associated with the outcome, and methylation
level is associated with the outcome, but the SNP and the
methylation level are not associated (Fig. 1, model 1). We
can only test this hypothesis within APOE and CR1 because
it is only in these two loci that genetic variation are associ-
ated with NP burden in our data set of moderate size. In
the CR1 region, there are no CpGs that reach significance
with the Benjamini-Hochberg correction; however, in the
APOE region there is one CpG that reaches significance for
NP, cg18799241 (P = 6.2 9 104) (Table 1). That CpG is
also modestly associated with APOE e4 (P = 0.04), suggest-
ing that cg18799241 may have some effect independent of
APOE e4. To assess this effect, we calculated that the APOE
e4 haplotype (adjusting for age at death, sex, study, and
batch) explains 15.4% of the variance in NP in our data.
cg18799241 explains 4.7% of the variance in this trait, and
the model that includes both the APOE e4 haplotype and
cg18799241 explains 16.3% of the variance. Thus, in the
case of the APOE locus, it is unclear if the variation in
methylation contributes to an individual’s risk of develop-
ing neuritic pathology independently of the effect of genetic
variation.
Assessing the CpG-mediated effect model
(2)
Since a significant association between the SNP and out-
come is required to test the CpG-mediated effect model, we
can only address the interesting question of whether meth-
ylation of certain CpGs mediates the effect a susceptibility
allele on AD pathology in the APOE (P = 3.8 9 1023)
and CR1 index SNP, rs6656401 (P = 0.017) (Table 1). The
analysis is outlined in our proposed models for the role of
DNA methylation (Fig. 1, model 2); here, we assess
whether adding the CpG to the model relating SNP to NP
attenuates the effect of the SNP on NP.
Of the 41 CpGs interrogated in the region of the APOE
gene by the Illumina beadset, the level of methylation of
eight CpGs is significantly associated with the APOE e4
haplotype (P-values between 0.006 and 5.1 9 1011); how-
ever, none of those CpGs met the multiple comparison
threshold for association with NP burden, although four
displayed suggestive evidence of association (P < 0.05)
Figure 4. AD susceptibility loci CLU displays multiple, independent
associations of CpG methylation with neuritic plaque (NP) burden.
The figure represents the results of analyses for the CLU region, with
the physical position presented on the x axis and log10 P-values
presented in the y axis. Diamonds represent the individual CpGs
across the gene region that were tested in the analysis. The state of
the chromatin in the dorsolateral prefrontal cortex of a cognitively
nonimpaired individual is presented below the x axis; this map is
based on the derivation of chromatin state in 200 bp segments using
data generated from the immunoprecipitation of chromatin marks.
The chromatin states are defined in a box at the top right of the
figure.16 The red diamonds are from the primary model testing for NP
association. The black diamonds report the results of the primary
model with the additional adjustment for the top CpG, cg16292768.
All P-values are reported in Table S1.
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(Table 3). When the CpGs are added to the model associ-
ating APOE e4 to NP, they do not diminish this associa-
tion, suggesting that the effect of the APOE e4 haplotype
on NP is not mediated by CpGs in which the level of
methylation is influenced by the APOE e4 haplotype.
In the region of the CR1 locus, there are 31 CpGs tar-
geted by the Illumina chip. We see a significant associa-
tion between the CR1 index SNP rs6656401 and NP
(P = 0.017) (Table 1). We also see associations between
rs6656401 and three CpGs, cg19393649 (P = 5.2 9 109),
cg26119563 (P = 1.8 9 107) and cg23026906
(P = 7.8 9 104) (Table S3). When controlling for each
of these CpGs, the association between rs6656401 and NP
burden did not change (Table 3) indicating that methyla-
tion at these CpGs does not mediate the effect of CR1 on
NP accumulation.
Assessing reverse causality model (3)
Using methods similar to those used in testing model 2,
we see no evidence of reverse causality in either the APOE
or the CR1 loci. Neither NP burden nor AD diagnosis
mediate the association between the genetic variants
(APOE e4 haplotype or CR1 risk allele) and the CpGs
(data not shown).
Assessing interaction model (4)
The final set of analyses explored the possibility of interac-
tions between the effect of CpGs and genetic variation
(Fig. 1, Model 4). We see a significant interaction between
the index SNP rs6656401 and two CpGs in the CR1 region,
cg10021878 and cg05922028 and suggestive for cg00175709
for both AD diagnosis (P’s for interactions, cg10021878
P = 0.001, cg05922028 P = 0.01, cg00175709 P = 0.05)
and NP burden (P’s for interactions cg10021878 P = 0.01,
cg05922028 P = 0.009, and cg00175709 P = nonsignifi-
cant) (Table 4). In all three CpGs, we see that the level of
methylation is negatively associated with NP burden and
odds of AD diagnosis in those subjects homozygous for the
protective allele (rs6656401TT) and positively associated in
those subjects bearing at least one copy of the risk allele
(rs6656401AT/AA) (Table 4). This interaction is also seen in
the variance explained by each CpG and a combination of
all three. In all three CpGs and for both NP and AD diagno-
sis, the CpGs explain more of the variance in the outcome
for those with the risk allele (rs6656401AT/AA) than those
without (rs6656401TT). For example, cg10021878 explains
19.2% of the variance in AD diagnosis for those with
rs6656401AT/AA but only 10.4% for those with rs6656401TT,
suggesting that DNA methylation within the CR1 locus
Table 2. Assessment of independent associations between CpGs and neuritic plaque burden.
BIN1
Position
SNP to CG association
CG to NP association
CG to NP association
Adjusted for rs744373
CG P-value b P-value b P-value
cg22883290 127800646 1.2E-04 4.42 3.7E-08 4.25 5.4E-07
CD2AP
Position
SNP to CG association
CG to NP association
CG to NP association
Adjusted for rs9349407
CG P-value b P-value b P-value
cg20172563 47487173 8.1E-25 3.48 7.5E-06 4.10 2.8E-06
CLU
Position
SNP to CG association
CG to NP association
CG to NP association
Adjusted for rs11136000
CG P-value b P-value b P-value
cg16292768 27467783 1.2E-09 2.34 3.7E-05 2.32 1.0E-04
cg08594681 27468684 1.1E-05 2.77 0.0008 2.68 0.002
cg13488078 27469338 0.0020 2.63 0.0029 2.46 0.009
MS4A6A
Position
SNP to CG association
CG to NP association
CG to NP association
Adjusted for rs610932
CG P-value b P-value b P-value
cg03055440 59950405 0.0099 2.16 0.0015 2.12 0.003
All models are adjusted for age at death, sex, study, batch, and bisulfite conversion fraction.
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plays a larger role in AD diagnosis for those with the CR1
risk allele than those without (Table 4). We did not find
evidence of significant interaction for any other SNP.
Discussion
In our focused analysis of regions previously associated
with genetic susceptibility to AD, we find a number of
alterations in DNA methylation that relate to NP burden.
In the ABCA7, CD2AP, CLU, and MS4A6A loci, we find
evidence for greater methylation of certain CpGs in rela-
tion to AD pathology and find that these changes occur
early, prior to the appearance of cognitive impairment, as
evidenced by the fact that the association remains after
subjects with mild cognitive impairment or AD proximate
to death are removed from the analysis. In these loci, the
associated methylation changes are not driven by the AD-
associated genetic variants, and there appears to be a single
effect in each locus. In the BIN1 locus, which has strong
evidence of association at multiple different sites (Fig. 2),
we see that the CpG that best captures the association,
cg22883290, is influenced in part by rs744373, the index
Table 3. Assessment of CpG mediation model with neuritic plaque burden and CpGs and AD diagnosis.
CR1
Position
CR1 to CpG association
CR1 to NP association
Adjusting for CpG1
CR1 to AD association
Adjusting for CpG
CG P-value b P-value b P-value
rs6656401 without adjusting for CpG 0.09 0.0169 0.65 1.0E-04
cg19373649 207817630 5.2E-09 0.09 0.0227 0.67 9.3E-05
cg26119563 207817838 1.8E-07 0.09 0.0208 0.66 1.0E-04
cg23026906 207819196 7.8E-04 0.08 0.0359 0.65 1.0E-04
APOE
Position
APOE e4 to CpG association
APOE e4 to NP
association
Adjusting for CpG1
APOE e4 to AD
association
Adjusting for CpG
CG P-value b P-value b P-value
any e4 without adjusting for CpG 0.41 3.7E-23 1.57 1.7E-13
cg09379229 45417668 5.1E-11 0.41 3.8E-22 1.63 1.7E-13
cg02613937 45395297 5.5E-11 0.44 2.9E-24 1.69 2.4E-14
cg14123992 45407868 2.5E-10 0.43 8.7E-24 1.63 1.1E-13
cg04406254 45407945 2.7E-10 0.42 3.4E-23 1.64 7.8E-14
cg07773593 45417793 4.0E-05 0.41 2.2E-22 1.57 2.6E-13
cg00397545 45417526 5.9E-04 0.43 7.2E-25 1.63 4.3E-14
cg08121984 45429870 0.004 0.41 7.0E-23 1.57 2.1E-13
cg01032398 45408121 0.006 0.41 2.2E-22 1.56 2.8E-13
All models are adjusted for age at death, sex, study, batch effect, and bisulfide conversion QC probes.
1Weak transcribed/low signal proximal to active regions.
Table 4. Interaction effects between CR1 and DNA methylation.
TT (n = 453) AT/AA (n = 239)
P-interactionb (SE) P-value R2 b (SE) P-value R2
Neuritic plaque burden
cg10021878 207669922 0.84 (0.35) 0.02 3.7% 0.76 (0.57) 0.18 4.7% 0.014
cg05922028 207669334 0.61 (0.89) 0.49 2.6% 3.57 (1.33) 0.008 6.9% 0.009
cg00175709 207670014 2.73 (1.06) 0.01 3.9% 1.26 (1.86) 0.48 4.2% 0.5
All three together 3.5% 6.5%
AD diagnosis
cg10021878 207669922 4.4 (1.5) 0.003 10.4% 4.9 (3.0) 0.1 19.2% 0.001
cg05922028 207669334 3.9 (3.6) 0.27 8.2% 12.1 (6.8) 0.07 19.4% 0.01
cg00175709 207670014 11.8 (4.4) 0.007 9.9% 5.5 (8.7) 0.53 17.9% 0.05
All three together 10.4% 21.0%
All models are adjusted for age at death, sex, study, batch effect, and bisulfide conversion QC probes.
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BIN1 SNP, however, its association with NP remains when
we account for the effect of this SNP. This suggests that
other, unknown factors influence its methylation and
perhaps AD susceptibility through alterations of DNA
methylation. Similarly, we see associations of methylation
levels to AD pathology that are unrelated to susceptibility
variants in the ABCA7, CD2AP, CLU, and MS4A6A loci.
Overall, it appears that methylation levels in many AD sus-
ceptibility loci relate to NP pathology and are relatively
independent of genetic variation. While these alterations
are not dependent on the presence of cognitive impair-
ment, it is not yet clear whether methylation changes are a
cause or an effect of AD pathology. However, the presence
of multiple, independent associations of CpG with NP in
loci such as BIN1, CLU, and MS4A6A further refines our
perspective on epigenomic changes in AD: the indepen-
dence of these associations suggests that they are not driven
by a single mechanism such as a simple increase in NP bur-
den. They are either driven by (1) different risk factors
whose effects on AD pathology converge on different geno-
mic segments within BIN1 and the other genes or (2) dif-
ferent molecular processes that are responding to the
presence of AD pathophysiology. Both models are plausible
and although our subjects are from a longitudinal study,
the brain samples are cross sectional which limits our abil-
ity to assess pathways and causality. Parsing out pathways
and models will require experimental investigation.
In two of the AD loci, we had the opportunity to evalu-
ate the possibility that DNA methylation mediates the effect
of the associated variant since both the CR1 index SNP and
the APOE e4 haplotype as well as some of the CpGs in each
locus are associated with NP burden and AD, which is a
prerequisite to formally test mediation. In the APOE locus,
we see that there are large DNA methylation changes that
are related to the APOE e4 haplotype, but these do not
appear to mediate the effect of the haplotype on the out-
come measures. On the other hand, we find evidence of a
different CpG, cg18799241, whose increased level of meth-
ylation is associated with greater NP burden, independent
of APOE e4. This suggests, as in the other loci above, that
nongenetic factors may be influencing AD pathology
through alterations in DNA methylation which can mani-
fest as alterations in transcriptional patterns.
In the CR1 locus, we find something unique among the
AD susceptibility loci: evidence for interaction between
the AD susceptibility allele and the level of methylation of
certain CpGs (Table 4). It is intriguing that the level of
methylation within a small segment of the CR1 gene may
have a differential effect on the accumulation of AD
pathology based on the presence of an intronic variant
22 kb away. The index SNP rs6656401 tags the haplotype
that contains a chromosomal segment duplication that
includes a duplicated LHR domain, LHR-S26 (Fig. 5), and
the resulting protein isoform (CR1 slow form, CR1-S)
Figure 5. Genomic architecture of the CR1 locus in relation to the major CR1 isoforms.
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encoded by this haplotype is structurally and perhaps
functionally26 different from the reference CR1 protein
isoform, CR1 fast (CR1-F). Thus, mechanistically, altering
the transcriptional state of CR1 may have different bio-
logic effects when the expression of the reference CR1-F
or CR1-S form of CR1 is expressed. Previous studies sug-
gested that the haplotype containing CR1-S is also associ-
ated with greater expression of this LHR-S form, so
influencing expression using a nongenetic mechanism
could also affect AD pathology. The associated CpGs are
found in a segment of DNA which is assigned to an “inac-
tive, poised promoter” conformation in our reference map
derived from cognitively nonimpaired subjects displaying
minimal brain pathology on autopsy.27 This suggests that
alterations in DNA methylation take place in a region of
the CR1 gene that can respond to dynamic changes.
Overall, our study targeted genomic regions implicated
in AD susceptibility because they harbor AD risk alleles,
indicating that other forms of genomic variation – in this
case DNA methylation – in the target organ are indepen-
dently associated with the risk of developing AD. One
limitation of our analysis is that our interrogation of
these loci is not comprehensive since we are limited to
the CpGs tested by the Illumina beadset; however, so far,
we do not see evidence that the effect of disease-associ-
ated genetic variation is mediated by alterations in chro-
matin conformation, as marked by changes in DNA
methylation. A picture of integration among different
sources of variation (genetic and epigenomic) is therefore
emerging in the brain of aging individuals, with these dif-
ferent factors contributing to the accumulation of AD
pathology and, ultimately, a diagnosis of AD. Further,
with the effects of loci such as BIN1 and CR1 that are
detailed in this manuscript, there are now precise hypoth-
eses that we can pursue in model systems to test the chal-
lenging question of the direction of causality for the
associated methylation changes.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. AD susceptibility loci ABCA7 display single
associations of CpG methylation with NP burden. The
figure represents the results of analyses for the ABCA7
region, with the physical position presented on the x axis
and log10 P-values presented in the y axis. Diamonds
represent the individual CpGs across the gene region that
were tested in the analysis. The state of the chromatin in
the dorsolateral prefrontal cortex of a cognitively nonim-
paired individual is presented below the x axis; this map
is based on the derivation of chromatin state in 200 bp
segments using data generated from the immunoprecipi-
tation of chromatin marks. The chromatin states are
defined in a box at the top right of the figure.16 The red
diamonds report the results of the primary analysis relat-
ing CpG methylation in the ABCA7 region and NP bur-
den using a model adjusted for age at death, sex, batch,
study, and bisulfite conversion fraction.
Figure S2. AD susceptibility loci APOE display single
associations of CpG methylation with NP burden. The
figure represents the results of analyses for the ABCA7
region, with the physical position presented on the x axis
and log10 P-values presented in the y axis. Diamonds
represent the individual CpGs across the gene region that
were tested in the analysis. The state of the chromatin in
the dorsolateral prefrontal cortex of a cognitively nonim-
paired individual is presented below the x axis; this map
is based on the derivation of chromatin state in 200 bp
segments using data generated from the immunoprecipi-
tation of chromatin marks. The chromatin states are
defined in a box at the top right of the figure.16 The red
diamonds report the results of the primary analysis relat-
ing CpG methylation in the APOE region and NP burden
using a model adjusted for age at death, sex, batch, study,
and bisulfite conversion fraction.
Figure S3. AD susceptibility loci CD2AP display single
associations of CpG methylation with NP burden. The
figure represents the results of analyses for the ABCA7
region, with the physical position presented on the x axis
and log10 P-values presented in the y axis. Diamonds
represent the individual CpGs across the gene region that
were tested in the analysis. The state of the chromatin in
the dorsolateral prefrontal cortex of a cognitively nonim-
paired individual is presented below the x axis; this map
is based on the derivation of chromatin state in 200 bp
segments using data generated from the immunoprecipi-
tation of chromatin marks. The chromatin states are
defined in a box at the top right of the figure.16
Table S1. Associations between CpG and NP burden and
CpGs and AD diagnosis, comparing models adjusting for
one, two or three associated CpGs.
Table S2. Associations between CpG and neuritic plaque
burden only among those with no cognitive impairment
at death.
Table S3. Associations between index SNPs and CpGs,
with only those meeting multiple comparison criteria.
Table S4. Assessment of independent associations
between CpGs and AD diagnosis.
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